Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety (Q39038994)

8 September 2017

title

Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety (English)

1 reference

8 September 2017

Yukiya Narita

1

1 reference

8 September 2017

Kei Muro

series ordinal

2

1 reference

8 September 2017

language of work or name

English

0 references

publication date

15 December 2016

1 reference

Expert Opinion on Drug Safety

8 September 2017

published in

1 reference

8 September 2017

volume

16

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

319-327

1 reference

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Comprehensive molecular characterization of gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Epidermal growth factor receptor family in lung cancer and premalignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Evolving novel anti-HER2 strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

EGFR signaling and drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

HER2 testing in gastric cancer: a practical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Clinical significance of intratumoral HER2 heterogeneity in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

VEGF-C expression is associated with the poor survival in gastric cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14740338.2017.1273348

10.1080/14740338.2017.1273348

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference